Education
About Us
Working with TipRanks
Follow Us
GH Research (GHRS)
NASDAQ:GHRS
GHRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.00 - $20.50
Previous CloseN/A
Volume14.35K
Average Volume (3M)254.53K
Market Cap
$558.25M
Enterprise Value$215.50M
Total Cash (Recent Filing)$100.79M
Total Debt (Recent Filing)$624.00K
Price to Earnings (P/E)―
Beta0.89
Next Earnings
May 14, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding62,028,145
10 Day Avg. Volume237,870
30 Day Avg. Volume254,532
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-684.12
Enterprise Value/Ebitda-5.63
Forecast
1Y Price Target
$32.38Price Target Upside259.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
GH Research News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessGH001 demonstrated significant reduction in depression symptoms in a placebo-controlled Phase IIb study.
Financial StabilityGH Research is well funded, with over $180 million in cash, to execute on broad development plans for GH001.
Market Expansion PotentialPositive efficacy signals in postpartum depression and bipolar depression highlight future expansion and potential upside.
Bears Say
Clinical HoldOne key focus for investors is on the ongoing clinical hold for GHRS' proprietary inhalation device.
Regulatory ChallengesRegulatory and commercial challenges are key investor concerns.
Trial Progression DelaysA full response submission to remove the clinical hold on the US trial using the proprietary aerosol device is anticipated, which indicates a delay in trial progression until mid-2025.
---
Ownership Overview
―
Insiders
2.21% Mutual Funds
43.06% Other Institutional Investors
54.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GHRS FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was $6.00 and its highest was $20.50 in the past 12 months.
What is GH Research’s market cap?
GH Research’s market cap is $558.25M.
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is May 14, 2025 which is in 30 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Feb 27, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.236 by $0.066.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -0.34.
How many shares outstanding does GH Research have?
GH Research has 62,028,145 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.236. Following the earnings report the stock price went down -2.917%.
Which hedge fund is a major shareholder of GH Research?
Currently, no hedge funds are holding shares in GHRS
---
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.38 (259.78% Upside)
$32.38 (259.78% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 41.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.18%
12-Months-Change
Fundamentals
Return on Equity
-19.58%
Trailing 12-Months
Asset Growth
-16.80%
Trailing 12-Months
Company Description
GH Research
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
---
GHRS Stock 12 Month Forecast
Average Price Target
$32.38
▲(259.78% Upside)
Technical Analysis
Prothena
―
Rocket Pharmaceuticals
―
Dianthus Therapeutics
―
Replimune Group
―
LENZ Therapeutics
―
Best Analysts Covering GHRS
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
-3.34%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -3.34% per trade.
---